{"id":"efgartigimod-iv","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297551","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to FcRn, efgartigimod IV prevents the recycling of IgG back into the circulation, leading to a decrease in IgG levels. This mechanism is thought to be beneficial in treating autoimmune diseases, such as myasthenia gravis, by reducing the levels of pathogenic antibodies.","oneSentence":"Efgartigimod IV is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn), thereby reducing the levels of immunoglobulin G (IgG) in the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:33.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized myasthenia gravis"}]},"trialDetails":[{"nctId":"NCT07217587","phase":"PHASE3","title":"Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-01-05","conditions":"Myasthenia Gravis","enrollment":115},{"nctId":"NCT06544499","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"argenx","startDate":"2024-10-18","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":69},{"nctId":"NCT07194850","phase":"PHASE2, PHASE3","title":"A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"argenx","startDate":"2025-10-20","conditions":"Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP","enrollment":24},{"nctId":"NCT07294170","phase":"","title":"ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis","status":"RECRUITING","sponsor":"argenx","startDate":"2025-12-19","conditions":"Myasthenia Gravis, MG, gMG","enrollment":70},{"nctId":"NCT04833894","phase":"PHASE2, PHASE3","title":"Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"argenx","startDate":"2021-10-26","conditions":"Generalized Myasthenia Gravis","enrollment":12},{"nctId":"NCT06299748","phase":"","title":"A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.","status":"RECRUITING","sponsor":"argenx","startDate":"2023-11-30","conditions":"Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":279},{"nctId":"NCT07284420","phase":"PHASE2","title":"ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","status":"RECRUITING","sponsor":"argenx","startDate":"2025-12-19","conditions":"AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG","enrollment":70},{"nctId":"NCT05374590","phase":"PHASE2, PHASE3","title":"Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis","status":"ENROLLING_BY_INVITATION","sponsor":"argenx","startDate":"2022-08-18","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":12},{"nctId":"NCT05810948","phase":"PHASE2","title":"A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)","status":"COMPLETED","sponsor":"argenx","startDate":"2023-02-21","conditions":"Lupus Nephritis","enrollment":73},{"nctId":"NCT04980495","phase":"PHASE3","title":"An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"argenx","startDate":"2021-12-16","conditions":"Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG","enrollment":69},{"nctId":"NCT06298552","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-04-16","conditions":"Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized","enrollment":119},{"nctId":"NCT05918978","phase":"PHASE2","title":"Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS","status":"TERMINATED","sponsor":"argenx","startDate":"2023-06-20","conditions":"Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome","enrollment":33},{"nctId":"NCT07072988","phase":"PHASE4","title":"Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-09-19","conditions":"Myasthenia Gravis, Generalized","enrollment":50},{"nctId":"NCT05817669","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)","status":"COMPLETED","sponsor":"argenx","startDate":"2023-04-04","conditions":"Primary Sjögren's Syndrome","enrollment":34},{"nctId":"NCT06860633","phase":"PHASE4","title":"Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-03-06","conditions":"Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis","enrollment":20},{"nctId":"NCT07011589","phase":"PHASE1, PHASE2","title":"Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)","status":"NOT_YET_RECRUITING","sponsor":"M. Peter Marinkovich","startDate":"2025-07","conditions":"Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa","enrollment":18},{"nctId":"NCT05633407","phase":"PHASE2","title":"Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS","status":"COMPLETED","sponsor":"argenx","startDate":"2022-09-23","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":53},{"nctId":"NCT05810961","phase":"PHASE2","title":"A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)","status":"TERMINATED","sponsor":"argenx","startDate":"2023-02-20","conditions":"Membranous Nephropathy","enrollment":8},{"nctId":"NCT06688253","phase":"PHASE4","title":"Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis","status":"NOT_YET_RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2024-11-15","conditions":"Myasthenia Gravis Crisis","enrollment":16},{"nctId":"NCT06587867","phase":"PHASE3","title":"Seronegative Myasthenia Gravis - Efgartigimod IV","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-06-01","conditions":"Efgartigimod, Generalized Myasthenia Gravis","enrollment":30},{"nctId":"NCT05927415","phase":"PHASE1","title":"A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod","status":"COMPLETED","sponsor":"argenx","startDate":"2023-07-17","conditions":"Renal Impairment","enrollment":33},{"nctId":"NCT03457649","phase":"PHASE1","title":"IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers","status":"COMPLETED","sponsor":"argenx","startDate":"2015-09-09","conditions":"Healthy Volunteers","enrollment":62},{"nctId":"NCT06118398","phase":"","title":"Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders","status":"UNKNOWN","sponsor":"Feng Jinzhou","startDate":"2023-11-05","conditions":"Neuromyelitis Optica, Efgartigimod","enrollment":24},{"nctId":"NCT03102593","phase":"PHASE2","title":"A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP","status":"COMPLETED","sponsor":"argenx","startDate":"2017-03-13","conditions":"Primary Immune Thrombocytopenia","enrollment":38},{"nctId":"NCT04735432","phase":"PHASE3","title":"Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"argenx","startDate":"2021-02-05","conditions":"Generalized Myasthenia Gravis","enrollment":110},{"nctId":"NCT05163834","phase":"PHASE1","title":"Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV","status":"COMPLETED","sponsor":"argenx","startDate":"2021-11-17","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT04564066","phase":"PHASE1","title":"A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"argenx","startDate":"2020-08-18","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT03334084","phase":"PHASE1","title":"A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects","status":"COMPLETED","sponsor":"argenx","startDate":"2017-10-11","conditions":"Bioavailability Study","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"efgartigimod IV","genericName":"efgartigimod IV","companyName":"argenx","companyId":"argenx","modality":"Biologic","firstApprovalDate":"","aiSummary":"Efgartigimod IV is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn), thereby reducing the levels of immunoglobulin G (IgG) in the body. Used for Generalized myasthenia gravis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}